Memory enhancing effect of Combined Alcoholic Extract of Cedrus deodara Loud. and Vitex Nirgundi in scopolamine-induced cognitive impairment in mice
Objective: Epidemiological studies of Indian population reveal that dementia is largely a hidden problem in India. Ayurveda claims several plants are beneficial in cognitive disorders.…Effects of levodopa on prosaccade performance and visual target eccentricity
Objective: To investigate whether the effect of levodopa on saccade is the same to visual targets of small and large eccentricities in Parkinson’s disease (PD)…Preserved white matter microstructure in Parkinson’s disease patients with levodopa-induced dyskinesia: Evaluation by neurite orientation dispersion and density imaging (NODDI)
Objective: Brain microstructure alteration using MRI in Parkinson's disease (PD) have not been well studied. We analysis the white matter alterations in Parkinson’s disease with…Long-Duration Response to Levodopa in advanced Parkinson’s Disease: Relevance for RCT on Disease-Modifying therapies
Objective: (1) To investigate the natural history of Parkinson’s disease (PD) in a cohort of newly diagnosed patients and (2) the response to acute levodopa…ODM-104 and optimized carbidopa dose show beneficial effect on levodopa PK in healthy subjects
Objective: To study the dose effects of a novel catechol-O-methyl transferase (COMT) inhibitor ODM-104 and the aromatic L-amino acid decarboxylase (AADC) inhibitor carbidopa on levodopa…Final MDS-UPDRS, Part IV Results of the EASE LID 2 Study: Long Term, Open-Label Study of ADS-5102 for Dyskinesia in Parkinson’s disease (PD) patients
Objective: An objective of this study was to evaluate the long-term duration of ADS-5102 effect on dyskinesia as assessed by the Unified Parkinson’s Disease Rating…Quantitative Assessment of Appendicular Bradykinesia in Parkinson’s Disease using Wearable Sensors
Objective: To quantify appendicular bradykinesia during a repetitive motor task in patients with Parkinson’s disease. Background: Bradykinesia is a cardinal motor symptom of Parkinson’s Disease…Depression (BDI-II) in Parkinson’s disease: Prevalence, types, and variables associated to major, minor and subclinical depression in COPPADIS cohort
Objective: To know the prevalence and characteristics of depression in PD patients of the COPPADIS-2015 cohort and its relationship with the other clinical aspects of…The anti-dyskinetic effect of the clinically-available 5-HT3 receptor antagonist granisetron in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effect of the serotonin 3 (5-HT3) receptor antagonist granisetron, a clinically-available anti-emetic, on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. Background: Dopamine replacement with L-DOPA…Does motor laterality affect the development of dyskinesia in patients with Parkinson’s disease?
Objective: To investigate the effects of motor laterality on the development of levodopa-induced dyskinesia (LID) in patients with de novo Parkinson’s disease (PD). Background: LID…
- « Previous Page
- 1
- …
- 34
- 35
- 36
- 37
- 38
- …
- 57
- Next Page »